Creation of a clinical database for primary nervous system tumors
Creation of a Clinical Database on Primary Nervous System Tumors
This study is creating a detailed database to help doctors learn more about primary brain tumors and improve treatment options for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1700 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle Academic / other |
| Locations | 1 site (Montpellier, Herault) |
| Trial ID | NCT04516720 on ClinicalTrials.gov |
What this trial studies
This study aims to create a comprehensive clinical database for patients diagnosed with primary central nervous system tumors (PCNST). It will collect data on the clinical, radiological, and biological characteristics of these tumors, as well as the effects of various oncological treatments and survival rates across different tumor subtypes. The database will facilitate the development of multicentric clinical studies and enhance understanding of rare histological subtypes, which currently have limited knowledge. By analyzing predictive and prognostic factors, the study seeks to improve treatment outcomes for patients with PCNST.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients aged 18 and older who have been diagnosed with primary central nervous system tumors and treated at the Montpellier Cancer Institute.
Not a fit: Patients with secondary lesions of the central nervous system or those not affiliated with a social protection scheme may not benefit from this study.
Why it matters
Potential benefit: If successful, this database could lead to improved treatment strategies and better prognostic assessments for patients with primary nervous system tumors.
How similar studies have performed: While the creation of clinical databases for rare tumors is a common approach, this specific initiative focuses on a comprehensive collection of data for a wide variety of PCNST subtypes, making it a novel effort in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient aged ≥ 18, no age limit; * Diagnosis of Primary central nervous system tumors ; * Patient treated at the Montpellier Cancer Institute, whatever the treatment received (systemic treatment, radiotherapy or exclusive supportive care); * For the retrospective part of the study, patient first treated at the Montpellier Cancer Institute between January 1rst, 2004 and the beginning of the prospective part; * Patient information for the retrospective (patient still alive at the beginning of the study) and prospective study. Exclusion Criteria: * Secondary lesions of the central nervous system; * Patient not affiliated to a social protection scheme; * Subject under tutelage, curatorship or safeguard of justice.
Where this trial is running
Montpellier, Herault
- Icm Val D'Aurelle — Montpellier, Herault, France (Recruiting)
Study contacts
- Study coordinator: Aurore MOUSSION, MD
- Email: DRCI-icm105@icm.unicancer.fr
- Phone: 04 67 61 31 02
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.